To achieve success with the first approach, interruption of Tg folding in thyrocytes can be achieved pharmacologically, whereas the second approach allows for mechanistic insight into the effect of specific mutations (that are known to be linked to congenital hypothyroidism in humans or animal models) on Tg protein folding and trafficking. The gene discussed is TG; the disease is congenital hypothyroidism.